Discounted Cash Flow Rating

Strong Sell

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Sell

Analyst Rating

Neutral

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Sell

Wall Street Data Solutions Rating

Neutral

B

AgeX Therapeutics, Inc. (AGE)

Pharmaceutical Preparations

https://www.agexinc.com

AgeX Therapeutics Inc is a biotechnology company engaged in the development and commercialization of novel therapeutics targeting human aging. The firm through its PureStem and induced Tissue Regeneration (iTR) technologies develops medicines designed to address some of the unsolved problems in aging. Its PureStem-derived cell-based therapeutic candidates in development are AGEX-VASC1, AGEX-BAT1 and AGEX-iTR1547.

1101 MARINA VILLAGE PARKWAY, SUITE 201
ALAMEDA, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/29/2018

Market Cap

27,758,325

Shares Outstanding

37,950,000

Weighted SO

37,951,261

Total Employees

N/A

Upcoming Earnings

N/A

Similar Tickers

MAIA --.--%

LRMR --.--%

GRPH --.--%

LYRA --.--%

LCTX --.--%

CVKD --.--%

ICCC --.--%

ONTTF --.--%

Beta

1.1870

Last Div

0.0000

Range

10.902699-35.17

Chg

-1.5000

Avg Vol

3980

Mkt Cap

27758325

Exch

AMEX

Country

US

Phone

510 671 8370

DCF Diff

15.0723

DCF

-3.9723

Div Yield

0.0000

P/S

239.2959

EV Multiple

-1.9661

P/FV

-7.1871

Div Yield %

0.0000

P/E

-1.4773

PEG

0.0381

Payout

0.0000

Current Ratio

0.6357

Quick Ratio

0.6239

Cash Ratio

0.6192

DSO

204.5259

DIO

0.0000

Op Cycle

204.5259

DPO

0.0000

CCC

204.5259

Gross Margin

0.3793

Op Margin

-87.2672

Pretax Margin

-180.7155

Net Margin

-180.7155

Eff Tax Rate

-0.1829

ROA

-1.9310

ROE

1.7271

ROCE

3.1605

NI/EBT

1.0000

EBT/EBIT

2.0708

EBIT/Rev

-87.2672

Debt Ratio

0.0593

D/E

-0.1495

LT Debt/Cap

-0.1060

Total Debt/Cap

-0.1757

Int Coverage

-2.7352

CF/Debt

-11.6646

Equity Multi

-2.5194

Rec Turnover

1.7846

Pay Turnover

0.0000

Inv Turnover

0.0000

FA Turnover

0.0896

Asset Turnover

0.0107

OCF/Share

-2.6925

FCF/Share

-2.6925

Cash/Share

3.1204

OCF/Sales

-64.7586

FCF/OCF

1.0000

CF Coverage

-11.6646

ST Coverage

-32.5195

CapEx Coverage

0.0000

Div&CapEx Cov

0.0000

P/BV

-7.1871

P/B

-7.1871

P/S

239.2959

P/E

-1.4773

P/FCF

-3.6952

P/OCF

-4.1226

P/CF

-4.1226

PEG

0.0381

P/S

239.2959

EV Multiple

-1.9661

P/FV

-7.1871

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jul 05, 13:51 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SAGE, COEP, AVDX on Behalf of Shareholders GlobeNewswire Inc. May 15, 22:52 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders GlobeNewswire Inc. Oct 30, 22:54 Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion GlobeNewswire Inc. Oct 30, 01:00 Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GitLab, Allarity, ZoomInfo, and Agenus and Encourages Investors to Contact the Firm GlobeNewswire Inc. Oct 29, 00:43 Agenus Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 5, 2024 Deadline to file Lead Plaintiff Motion. Benzinga Oct 25, 00:02 SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit GlobeNewswire Inc. Oct 24, 00:06 Sage Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. October 28, 2024 Deadline to file Lead Plaintiff Motion Benzinga Oct 23, 03:05 SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit GlobeNewswire Inc. Oct 20, 01:45 SAGE DEADLINE: RLF, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Oct 18, 00:42 ROSEN, A TOP-RANKED LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important October 28 Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Oct 12, 01:07 ROSEN, A LEADING LAW FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Oct 03, 22:44 ROSEN, LEADING INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Sep 30, 01:08 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Sep 29, 21:43 ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN GlobeNewswire Inc. Sep 26, 23:26 ROSEN, LEADING TRIAL ATTORNEYS, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE GlobeNewswire Inc. Sep 21, 00:05 AGEN Class Action Notice: Robbins LLP Reminds Agenus Inc. Stockholders of Pending AGEN Class Action Lawsuit Benzinga Sep 17, 22:37 Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE) GlobeNewswire Inc. Sep 15, 20:00 AGEN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Agenus Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! GlobeNewswire Inc. Sep 14, 13:36 ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE Benzinga Sep 11, 23:55 INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Sage Therapeutics, Inc. (SAGE) on Behalf of Investors

Revenue Product Segmentation